Proceedings of the 22nd Annual ASTR Meeting 1339

7) EVALUATION OF PULMONARY FUNCTION CHANGES BY POSTOPERATIVE RADIOTHERAPY IN PATIENTS WITH LUNG CANCER

Noah C. Choi, M.D.*+ and Homayoun Kazemi, M.D.***

Department of Radiation hledicine*, Department of yedicine**, Massachusetts General Hospital, Department of Radiation Therapy , Department of Medicine*,

tiarvard Medical School, Boston, MA

Changes of pulmonary functions as a result of a lobectomy or pneumon- ectomy have been reported. However, the changes of pulmonary functions after postoperative radiotherapy for Nl, incidental N2, T3 stage lung cancer have not been described. From January 1977 to February 1979, 31 patients had pul- monary function test (PFT) before postoperative radiotherapy approximately 4 weeks after the surgery. Repeat PFT was performed in 17 of 31 patients lo- 12 months after the postoperative radiotherapy. Surgical procedures consisted of lobectomy in 15 patients and pneumonectomy in 3 patients. Target volume for radiotherapy included the ipsilateral hilum, the entire mediastinum and both supraclavicular areas. Total dose 5600 rad was delivered in 5.5-6 weeks with da'ly dose 183-200 rad. For patients with lobectomy, AP, PA parallel opposing portals (POP) were used up to 3600 rad and then additional 2000 rad was delivered by AP, RPO and LPO. For patients with pneumonectomy, AP, PA, POP was used up to 4400 rad and then additional 1200 rad was delivered by AP PA oblique opposing portals. As shown in Table I, parameters of pulmonary air flow improved from 1.53'1 -33': except -2:. changes for FLOW 50% VC (L/MIN). Parameters of pulmonary volume showed no change or slight increase in TLC and RV, and slight decrease in FRC and RVJTLC. Pa02 showed slight decrease (-2') and there was no change in PaC02. This study indicates that postoper- ative radiotherapy can be carried out without much damage to patients' pulmonary function.

(8) PRIMARY RADIOTHERAPY FOR STAGE I AND II BREAST CANCER: FOLiOWUP REPORT FROM FOUR EAST COAST UNIVERSITY HOSPITALS

Leonard R. Prosnitz, M.D., Ira S. Goldenberg, M.D., Jay Harris, M.D., Martin B. Levene, M.D., Samuel Hellman, M.D., Paul E. Wallner, D.O., Luther W. Brady, M.D., Barbara F. Danoff, M.D., Simon Kramer, M.D.

Dept. of Therapeutic Radiology, Yale tiniv. School of Medicine, New Haven, CT; Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA; Dept. of Radiation Therapy, Hahnemann Medical College, Philadelphia, PA; Dept. of Radiation Therapy, Thomas Jefferson University, Philadelphia, PA

This report presents followup information on 150 patients with clinical stage I or II breast carcinoma treated primarily with local excision and radiation rather than mastectomy at 4 East Coast university hospitals. An additional 143 patients are reported for a total of 293 patients treated primarily with radiation at the 4 centers between 1962 and 1978.

Treatment techniques were similar at all institutions consisting of local excision of the mass followed by 5000 rads in 5 weeks to the entire breast, supraclavicular, axillary and internal mammary lymph nodes and then a boost dose of 1000-2000 rads to the area of the primary tumor, either with an iridium implant or electron beam.

Five and 10 year overall survival and relapse-free survival (RFS) data are shown in the following table.